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Introduction
Considerable attention and research dollars have focused 
on the cytokine interleukin-17 (IL-17 or IL-17A) and the 
pathology associated with aberrant IL-17 signaling. In 
many cases, an excess of IL-17 is associated with ab-
normal inflammation, implicated in rheumatoid arthritis, 
asthma, psoriatic arthritis, ankylosing spondylitis, systemic 
lupus erythematosus and autoimmune encephalo myelo-
pathy (reviewed in [1]). Not surprisingly, IL-17 and related 
cytokines have become a prime target for pharma ceutical 
management of these diseases (reviewed in [2]). Targeted 
biologics are an appealing method to combat pathologic 
inflammation while avoiding non-specific immuno sup-
pression. ere are currently Food and Drug Adminis-
tration-approved monoclonal antibodies for the treat-
ment of rheumatologic and autoimmune diseases 
targeting various cytokines and immune factors, includ-
ing TNF-α, IL-1, cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4), B cells (CD20), IL-6, IL-12/23p40, 
and so on. Although not originally designed with that 
intent, many if not all of these drugs target the IL-17 
pathway. Drugs are currently in development that target 
the T-helper cell 17 (17) pathway, including IL-17 and 
its receptor, IL-23p19 and IL-22, among others [3-9]. 
Rigorous clinical trials and post-marketing studies are 
essential to reveal possible unexpected consequences of 
targeted immune blockade. In addition, attention to 
‘experiments of nature’ in which mutations lead to 
alterations in cytokine pathways are a useful adjunct to 
predict adverse effects of the new biologic agents. is 
review will focus on the IL-17/17 pathway and muco-
cutaneous candidiasis, an opportunistic infection asso-
ciated with immunodeficiency, with reference to the 
known or potential impact of cytokine blockade.
IL-17 is secreted by the 17 subset of CD4+ lympho-
cytes, as well as CD8 T cells and innate cells, including 
natural killer T cells, lymphoid tissue inducer cells, innate 
lymphoid cells and γδ-T cells [10]. 17 cells are highly 
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protective against extracellular pathogens and can parti-
ci pate in immunity to intracellular bacteria and perhaps 
certain viruses, especially at mucosal surfaces (reviewed 
in [11]). A notable extracellular pathogen at the oral 
mucosa is C. albicans, a commensal yeast that frequently 
colonizes the mouth, colon or vagina in healthy indivi-
duals [12]. Asymptomatic colonization generally only 
progresses to disease in the face of an additional risk 
factor, such as immunosuppression, disruption of normal 
barriers, surgery or broad spectrum antibiotics [13-15]. 
We recently demonstrated in mice that the IL-23/IL-17 
axis of immunity is critical for immunity to Candida in 
the oropharynx using mice lacking IL-23 or either IL-17 
receptor subunit (IL-17RA and IL-17RC) [16,17]. Simi-
larly, immunity to dermal and disseminated candidiasis 
in mice is regulated by the IL-17 pathway [18,19]. In 
humans, the majority of Candida-specific memory 
T  cells express IL-17 and CCR6 (a Th17 marker) [20], 
clearly linking the IL-17 pathway to antifungal immunity 
(Figure 1).
Candida infections of the mucosal, nail or skin surfaces 
are termed mucocutaneous candidiasis. In patients with 
an underlying genetic or immune defect leading to 
susceptibility to these infections, the disease is often 
persistent and chronic, termed chronic mucocutaneous 
candidiasis (CMC). The direct manifestations of CMC 
are Candida plaques (usually C.  albicans) on the oral, 
esophageal or genital mucosa or thickened skin and nails 
(reviewed in [21]). Susceptible individuals may also 
experi ence recurrent infections with dermatophytes. 
Although symptoms can be benign, they often cause 
significant morbidity due to pain, weight loss or failure to 
Figure 1. Normal immune responses to mucosal C. albicans and genetic defects associated with chronic mucocutaneous candidiasis. 
Various defects in the normal immune pathway from C. albicans sensing at the pattern recognition receptor (especially C‑type lectin receptors 
(CLRs)) to IL‑17 action on target cells can result in susceptibility to chronic mucocutaneous candidiasis. Known deficiencies associated with chronic 
mucocutaneous candidiasis include Dectin‑1, CARD9 (caspase recruitment domain‑containing protein 9), IL‑12/23 (p40 deficiency), IL‑12/23 
receptor (IL12Rβ1 deficiency), STAT3 (signal transducer and activator of transcription 3), IL‑17A, IL‑17F and IL‑17RA. Gain‑of‑function mutations in 
STAT1 can also inhibit the normal Th17/IL‑17 pathway. AIRE mutations resulting in anti‑cytokine antibodies disrupt the pathway through direct 
interference with IL‑17 (including IL‑17A and IL‑17F, which can form homodimers and heterodimers).
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thrive, or more severe secondary complications such as 
squamous cell carcinoma, debilitating hands, esophageal 
stricture or cerebral aneurysms [22-25]. Interestingly, 
muco cutaneous candidiasis is rarely associated with 
disseminated candidal disease [26]. In the past few years, 
multiple genetic etiologies causing this disease have been 
described. Strikingly, most relate directly or indirectly to 
defects in IL-17, supporting the notion that not only is 
the IL-17 pathway critical for regulating anti-fungal 
immunity, but defects in IL-17 predispose primarily to 
infection with C.  albicans and surprisingly few other 
microbes.
Defects in the IL‑17 pathway
AIRE deficiency
Autoimmune polyendocrinopathy syndrome-I (APS-I), 
also known as autoimmune polyendocrinopathy candi-
diasis ectodermal dystrophy (APECED), is an autosomal 
recessive disorder caused by mutations in the auto-
immune regulator (AIRE) gene. Mutations in AIRE lead 
to aberrant thymic self-tolerance mechanisms and loss of 
thymic deletion of autoreactive T cells. The classic triad 
of this disease is CMC, typically presenting by age  6, 
hypoparathyroidism and adrenocortical failure [27,28]. 
The prevalence of the disease varies worldwide, but is 
highest in Iranian Jews (about 1:9,000), Sardinians 
(1:14,000), and Finnish populations (1:25,000), with men 
and women equally affected (reviewed in [25]). A wide-
range of disease manifestations has been described, 
including, in descending order of prevalence, dental 
enamel dysplasia, nail dystrophy, alopecia, ovarian 
failure, vitiligo, diabetes mellitus, testicular failure and 
hypo thyroidism. CMC is nearly universal in APS-I 
patients [27,29], but they are not prone to other infec-
tions. The lone infectious susceptibility associated with 
this disease was initially mysterious, but now is tied to 
neutralizing autoantibodies against cytokines detected in 
these patients [30]. The most common anti-cytokine 
autoantibodies are directed against the type I interferons 
(IFNs) and Th17-related cytokines, notably IFN-ω (100% 
of patients), IFN-α (95%), IL-22 (91%), IL-17F (75%), and 
IL-17A (41%) [27]. Similar high prevalence of antibodies 
against IL-17A, IL-17F and IL-22 has been found in 
APS-1 in other studies [31]. Plasma from patients with 
auto antibodies against IL-17 abolishes IL-17 responsive-
ness (measured by IL-6 production) in fibroblasts, con firm-
ing that these antibodies interfere with IL-17 activity [31].
Although APS-1 is not the only human disease 
resulting from abnormal autoantibodies, it is the only 
such disease associated strongly with CMC. This is most 
likely due to the unique spectrum of anti-cytokine auto-
antibodies produced as a result of AIRE deficiency. For 
example, a different pattern of anti-cytokine auto anti-
bodies is found in patients with thymoma. Thymoma 
patients have a high prevalence of antibodies to IFN-ω, 
IFNα and IL-12, but a low prevalence of antibodies to 
IL-22, IL-17F or IL-17A [27]. CMC is an unusual 
manifes tation of thymoma, but its occurrence correlates 
with the presence of autoantibodies against both IL-17A 
and IL-22 [30], further supporting the concept that 
neutralizing Th17-specific cytokines increases suscepti-
bility to candidiasis. Thus, the pathogenesis of APECED 
with respect to CMC seems to be tightly linked to 
neutral izing Th17 cytokines, suggesting that IL-17 
neutrali zation applied in other settings increases the risk 
for CMC.
IL‑17 receptor mutations
The most direct evidence for a role in the IL-17 pathway 
in host resistance to CMC comes from a recent report of 
a case of homozygous mutation in the IL-17A receptor 
(IL17RA). The mutation was found in a French child of 
Moroccan descent with autosomal recessive CMC [32]. 
The child presented with Candida dermatitis starting in 
the neonatal period and Staphylococcus aureus dermatitis 
at 5 months of age. Sequencing of multiple genes related 
to IL-22 or IL-17 signaling (IL22, IL22RA1, IL10RB, 
IL17A, IL17F, IL17RA, IL17RC) revealed a homozygous 
nonsense muta tion in the IL17RA gene (c.850C>T/
c.850C>T), which results in a premature stop codon in 
the extra cellular domain of the receptor. The child’s 
parents and siblings were heterozygous for the allele and 
asympto matic. A database of healthy controls from 52 
ethnic groups, as well as French and Moroccan controls, 
failed to reveal any other cases of this mutation. The 
patient’s blood and tissue were studied in more detail, 
which revealed a lack of IL-17RA protein on the surface 
of fibroblasts and peripheral blood mononuclear cells. 
IL-17RC, IL-22RA1, IL-17A and IL-22 expression levels 
were normal. The patient’s fibroblasts did not respond to 
IL-17A or IL-17F in terms of producing prototypical 
IL-17 target proteins such as IL-6 or growth-regulated 
oncogene-α (GROα, also known as CXCL1 or KC in 
mice). Importantly, normal function was restored upon 
transfection of fibroblasts with wild-type IL17RA, verify-
ing that this manifestation was not from another 
undetected mutation. The phenotype of homozygous 
IL17RA mutation in humans is consistent with findings 
that IL-17RA- and IL-17RC-deficient mice are more 
susceptible to oropharyngeal candidiasis, and suggests 
that data from mouse models are a good predictor of 
human susceptibility to candidiasis [16,17].
IL‑17A deficiency
A kindred with autosomal dominant CMC who lack the 
IL-17 family member IL-17A and Th17 cells has been 
described [28]. The exact defect is unknown but it 
appears to be posttranscriptional since IL‑17 mRNA 
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levels were preserved [28]. Additional patients with CMC 
have been described with decreased production of 
IL-17A and IL-22 of unknown underlying etiology [33]. 
The emerging evidence of a role for IL-17A in human 
susceptibility to Candida is supported by work in mice. 
For example, IL-17A-deficient mice have impaired clear-
ance of C. albicans infection from the skin [19].
The role of IL-22 is less clear, as IL22-/- mice are not 
susceptible to either dermal or oral candidiasis [17,19]. In 
a gastric model of candidiasis in mice, IL-22 does appear 
to be protective [34], perhaps due to its well known role 
in promoting epithelial repair in the mucosa [35]. More 
work is needed to determine its precise contribution to 
antifungal immunity.
IL17F mutation
A form of autosomal dominant CMC with incomplete 
penetrance results from mutation in the IL-17 family 
member IL17F [32]. This mutation was first described in 
four members of a family from Argentina with autosomal 
dominant inheritance of CMC. A thorough analysis of 
genes related to IL-17 signaling revealed a heterozygous 
missense mutation in the IL17F gene of the index case. 
The mutation (c.284C>T) resulted in the replacement of 
a conserved serine with leucine. This mutation was not 
found in the control patient database. Based on compu-
tational analysis, the missense mutation is predicted to 
interfere with cytokine to receptor binding. All tested 
members of the kindred with CMC were heterozygous 
for this mutation. Two apparently healthy family 
members also had the allele, suggesting incomplete 
penetrance. By flow cytometry, IL-17F-expressing T cells 
were absent in affected family members. In vitro studies 
of the mutant protein revealed defective binding to 
IL-17RA on fibro blasts, with weaker IL-6 and GRO-α 
induction. Peripheral blood mononuclear cells also had 
impaired induction of cytokines when stimulated with 
the mutant protein.
This finding was somewhat surprising, as IL-17F is not 
a strong agonist of the IL-17 receptor compared to 
IL-17A, and IL17F‑/‑ mice were not highly susceptible to 
disseminated candidiasis [36]. However, IL-17A and 
IL-17F form both homodimers and heterodimers [37], 
and the mutant IL-17F identified in this patient cohort 
blocks signaling from the IL-17A:F form of the cytokine 
[32]. Thus, blockade of either IL-17A or IL-17F may 
predispose to mucosal candidiasis.
Hyper‑Ige syndrome
The hyper-IgE syndromes (HIESs, Job’s syndrome) com-
prise a group of primary immunodeficiencies charac-
terized by elevated serum IgE, dermatitis and recurrent 
infections primarily of the skin and lungs. The infectious 
predilections in autosomal-dominant HIES include CMC 
and bacterial infections with S. aureus, Streptococcus 
pneumonaie and Haemophilus influenzae. Most cases of 
HIES are sporadic, resulting from a dominant negative 
mutation in the signal transducer and activator of 
transcription 3 (STAT3) [38,39]. The mutations are 
primarily in the DNA-binding domain or Src homology 2 
(SH2) domain of STAT3 and lead to the impaired 
generation of Th17 cells [40]. Since STAT3 is downstream 
of IL-22, cellular responses to this Th17-derived cytokine 
are also impaired. In fact, IL-17 production by T cells is 
absent in cells from HIES individuals after stimulation 
with Staphylococcus enterotoxin B or C.  albicans [41]. 
The mutations in STAT3 result in decreased expression of 
regulator retinoid-related orphan receptor γt (RORγt), a 
transcription factor required for IL-17 expression, and 
decreased differentiation into Th17 cells by naïve CD4+ 
T cells [42]. The specific infectious susceptibility of HIES 
patients to skin and pulmonary infections appears do be 
due to a site-specific requirement of Th17 cytokines to 
produce antimicrobial factors, found both in skin and 
salivary gland tissue [43,44].
Autosomal recessive HIES is a related, but distinct 
disorder. Most patients affected by this disease are 
deficient in dedicator of cytokinesis 8 (DOCK8), leading 
to impaired T-cell activation and maintenance of 
memory. As in autosomal-dominant HIES, these patients 
have elevated IgE levels, eczema, recurrent bacterial 
infec tions and CMC [45,46]. The unique disease mani fes-
tations include susceptibility to recurrent viral infec tions 
(most commonly herpes viruses, molluscum contagiosum 
virus and human papillomaviruses), asthma, severe food 
allergies, malignancy at young age and unusual auto-
immune diseases. Some DOCK8-deficient patients have 
decreased numbers of Th17 cells (reviewed in [47]). One 
additional case of autosomal recessive HIES associated 
with a tyrosine kinase 2 (Tyk2) deficiency has been des-
cribed [48]; however, a case of Tyk2 deficiency resulting 
in a phenotype without eczema, candidiasis or hyper-IgE 
has also been reported [49]. Tyk2 is a member of the 
Janus kinase (JAK) family that signals downstream of 
IL-23 and hence is needed for efficient Th17 maintenance 
in vivo. Accordingly, HIES can be caused by various 
genetic lesions, but the common thread appears to be 
regulation of the IL-17/Th17 pathway.
STAT1 mutation
Using a genome-wide approach based on whole-exome 
sequencing, gain-of-function STAT1 mutations were 
recently associated with isolated CMC [50]. Twelve 
missense mutations were found in 47 patients from 20 
kindreds of CMC without other clinical features. 
These mutations were in the coiled-coil domain of 
STAT1, in a pocket near residues essential for STAT1 
dephosphorylation. Mutations at this site result in 
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gain-of-function STAT1 phosphorylation leading to 
enhanced transcription of STAT-1-dependent genes in 
response to various cytokines. The STAT1 mutant 
products enhance cellular response to cytokines IFNα/β, 
IFNγ and IL-27, which are all known inhibitors of the 
Th17 pathway. These patients had disease involving a 
range of cutaneous and mucosal sites, including nails, 
oral cavity, oro pharynx, genital mucosa, skin and 
esophagus. Some patients had thyroid autoimmunity (8 
of 47) and one had systemic lupus erythematosus. 
Squamous cell carcinoma was the cause of death in four 
patients, and cerebral aneurysm in two.
STAT1 mutations were also demonstrated in 14 auto-
somal dominant cases of CMC from five families [51]. In 
addition to CMC, members of one family suffered from 
various autoimmune diseases (autoimmune hepatitis, 
autoimmune hemolysis, pernicious anemia and antiphos-
pho lipid antibodies) as well as symptomatic cytomegalo-
virus infection and Pneumocystis carinii pneumonia. 
Three families suffered from hypothyroidism while the 
fifth family did not have associated autoimmune disease. 
Three families had histories of oral squamous-cell 
carcinoma or esophageal cancer. Analysis revealed 
hetero zygous mutations in STAT1 in only the affected 
family members. These mutations were located in the 
coiled-coil domain of STAT1, and led to defective Th1 
and Th17 responses with reduced production of INF-γ, 
IL-17 and IL-22 in response to Candida stimulation [50]. 
Therefore, STAT1 gain-of-function mutations result in 
CMC through a similar final pathway as other IL-17 
signaling defects.
IL‑12rβ1 or IL‑12p40 deficiency
Patients with inborn errors of the IL-12/IL-23 or IFNγ 
signaling axis, also known as Mendelian susceptibility to 
mycobacterial diseases (MSMD), are susceptible to 
myco bacteria. Infectious susceptibility includes weakly 
virulent species of mycobacteria such as the bacillus 
Calmette-Guérin (BCG) vaccine and severe disease 
caused by Salmonella serotypes [52]. A recent review of 
132 patients with the most common form of this disease, 
IL-12Rβ1 deficiency, found that 24% have mucocutaneous 
disease caused by Candida albicans, usually manifesting 
as recurrent oral thrush [53]. The two mutated genes 
associated with MSMD are IL12B and IL12RB1. Patients 
with IL12B null mutations lack the IL-12p40 subunit, a 
shared component of both IL-12 and IL-23 [54]. Similarly, 
the IL12RB1 gene encodes the shared chain of the IL-12 
and IL-23 receptors (Figure  1). The susceptibility to 
mycobacterial disease is almost certainly rooted in the 
deficiency in IL-12 signaling and Th1 cells, which are 
central to clearance of intracellular pathogens. In 
contrast, defective IL-23 signaling impairs the expansion 
and maintenance of Th17 cells and IL-17 signaling. 
Patients with mutations in IL12RB1 and IL12B have low 
proportions of IL-17A-producing T cells in circulation, 
which likely explains the susceptibility to CMC [40].
C‑type lectin receptor pathway defects
Dectin‑1 defects
Dectin-1 is a fungal pattern recognition receptor (PRR) 
that recognizes β-glucans, carbohydrates located in the 
cell wall of the yeast form of Candida (Figure 1). C-type 
lectin receptors (CLRs) such as Dectin-1 are emerging as 
important mediators of innate anti-fungal immunity, 
although there are still many unanswered questions 
about their specific roles in vivo [55]. Studies of Dectin-1 
knockout mice revealed increased susceptibility to 
gastrointestinal colonization with C. albicans and varying 
susceptibility to disseminated candidiasis, depending on 
the strain of Candida used (reviewed in [56]). In humans, 
the Dectin-1 polymorphism Y238X leads to a premature 
stop codon and increased susceptibility to CMC in three 
described homozygous patients [57]. CMC in these 
patients was characterized by vulvovaginal candidiasis or 
onychomycosis with Trichophyton rubrum. Monocytes 
and macrophages in these patients had lower fungal-
sensing capacity, with decreased production of IL-6 after 
stimulation with β-glucan, heat-killed C. albicans or live 
C.  albicans. Consequently, impaired Th17 generation 
resulted in reduced IL-17 production. Compared to other 
genetic lesions that promote CMC, however, disease was 
mild in these patients, suggesting that their susceptibility 
may be multifactorial. Furthermore, while family members 
heterozygous for the polymorphism exhibited an inter-
mediate reduction in proinflammatory cytokines, there 
was only mild transient candidal disease in one person. 
Follow-up studies revealed that this polymorphism was 
found on a population-wide search in individuals from 
Europe and Africa and is associated with increased 
Candida colonization in immunosuppressed hemato-
poietic stem cell transplant recipients [57,58]. Therefore, 
Dectin-1 appears to contribute to immune recognition of 
Candida and presents a link between pathogen sensing 
and IL-17 production.
CARD9 defects
Caspase recruitment domain-containing protein 9 
(CARD9) is a signal transducer downstream of many 
fungal PRRs, including most of the CLRs. Mice deficient 
in CARD9 exhibit severely reduced TNF-α and IL-2 
production in response to zymosan, a yeast cell wall 
component principally composed of β-glucans, but not 
other PRR ligands [59]. As discussed above, the primary 
receptor for β-glucans is Dectin-1, a CLR that transduces 
signals via spleen tyrosine kinase (Syk) activation and PKCδ, 
ultimately activating the NF-κB and mitogen-activated 
protein kinase (MAPK) pathways [60-62]. CARD9-deficient 
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mice have an impaired immune response to systemic 
challenge with C.  albicans, with accelerated mortality 
and higher organ fungal burdens compared to hetero-
zygous littermates [59]. CARD9 defects in humans were 
first reported in a large consanguineous Iranian family 
with CMC and peripheral dermatophytosis [63]. CARD9 
deficiency results from a homozygous point mutation, 
Q295X, on chromosome 9q leading to a pre mature stop 
codon and loss-of-function. The mutation was not found 
in healthy family members or 230 healthy unrelated 
controls. Patients with this defect have low proportions 
of IL-17A-producing T cells and an almost complete 
defect in the generation of a Th17 response. The 
phenotype in CARD9-deficient patients is distinct from 
that of other genetic causes of CMC in that it also 
includes susceptibility to invasive candidiasis. Three of 
eight affected family members died of central nervous 
system candidiasis. The fact that the phenotype seems to 
be so severe compared to the Dectin-1-deficient cohort 
suggests that other CARD9-utilizing CLRs, such as 
Dectin-2 and/or Mincle, are equally or more important 
for anti-Candida immunity.
Other causes of chronic mucocutaneous 
candidiasis
There are additional causes of human CMC with defects 
in known pathways, many of which can be readily linked 
to Th17. Inborn errors of NF-κB activation, known as 
IκBα deficiency, can cause this disease. IL-17 activates 
NF-κB directly [64,65], as do the CLRs that bind fungal 
cell wall components and promote Th17 development. 
Deficiency in NF-κB activity leads to severe impairment 
in T-cell receptor signaling and susceptibility to CMC 
[65]. Consistently, non-specific inherited defects in T-cell 
immunity, including DiGeorge syndrome and severe 
combined immunodeficiency (SCID), are associated with 
susceptibility to CMC [14]. HIV/AIDS patients are 
extremely susceptible to oral candidiasis, which is linked 
to reduced CD4+ T-cell counts. Recent data indicate that 
Th17 cells are lost preferentially during HIV infection, 
perhaps explaining the specific array of opportunistic 
infections associated with AIDS [66]. Non-specific 
immuno suppression secondary to cancer chemotherapy 
or immunosuppressive agents also increases suscepti-
bility to CMC [15].
Some secondary conditions not directly related to 
T cells or IL-17 also predispose to CMC, such as hyper-
glycemia or long-term use of broad-spectrum antibiotics 
[67,68]. Moreover, the salivary gland plays a critical role 
in oral mucosal immunity. CMC is prevalent in 
individuals with dentures, with salivary defects such as 
Sjögren’s syndrome, following head or neck radiation 
therapy or with drugs causing xerostomia [67]. We 
recently showed that HIES patients have defective 
salivary killing activity towards C.  albicans, associated 
with reduced levels of antimicrobial peptides such as 
defensins and salivary histatins [44]. Although IL-17 can 
signal directly on salivary gland acinar cells [44], these 
defects may also be independent of the IL-17 pathway.
Biologic therapies and chronic mucocutaneous 
candidiasis
The increased understanding of the Th17-IL17 axis in the 
pathogenesis of autoimmune conditions has given rise to 
new classes of biologics. In addition to currently available 
agents that broadly target inflammatory cytokines or 
T-cell activation, newer drugs with specificity for Th17 
effector cytokines (IL-17, IL-21, IL-22) and inhibitors of 
signaling molecules important for Th17 cell activation 
are currently in early clinical trials [69]. The rise of these 
agents brings to the forefront the important question of 
susceptibility to CMC in patients receiving more targeted 
biologic therapies. Currently approved agents have thus 
far not been associated with susceptibility to CMC 
[70,71]. Cumulative data demonstrate that the primary 
susceptibilities are to Mycobacterium tuberculosis, 
(presumed) bacterial sino-pulmonary infections, Histo‑
plasma capsulatum and JC virus (all associated with 
TNFα-inhibitors) [72,73]. Surprisingly, IL-1 receptor 
antagonists, IL-6 receptor antagonists and CTLA4 
agonists are not associated with increased infectious risk 
compared with placebo (although there is trend toward 
susceptibility) [71,74]. Additionally, antibodies against 
the shared IL-12/23p40 subunit are associated with a 
slightly increased risk for (presumed bacterial) sino-
pulmonary infections, but not for CMC [75-78]. 
Similarly, newer agents, which inhibit the JAKs and Syk, 
are associated with increased risk of (presumed bacterial) 
sino-pulmonary infections, but not CMC [79,80]. This is 
perhaps somewhat surprising, since the JAKs, STATs and 
Syk are all important for induction of Th17 cells down-
stream of multiple cytokines and/or PRRs. Although the 
cumulative clinical trial evidence suggests that biologics 
do not confer susceptibility to CMC, it is important to 
bear in mind that with their increased use, biologics may 
be found to increase susceptibility to CMC in patients 
with otherwise subclinical mucosal Candida coloniza-
tion. This may especially be true when biologics are 
coupled with other predisposing factors (for example, 
corticosteroid use). The results of on-going large scale 
phase 4 studies may identify a subset of patients with a 
propensity to develop CMC that would benefit from 
prophylaxis with anti-fungal agents.
Perspectives
In the past several years, many causes of isolated CMC 
and CMC associated with other abnormalities have been 
elucidated. Combined with the recent work on IL-17 and 
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Th17 cells in mice, this has led to an expanded 
understanding of the mechanism of host defense from 
C. albicans at mucosal surfaces and the role of IL-17 in 
immunity from infection. IL-17 is essential for normal 
resistance to Candida infection in the oral mucosa, 
vagina mucosa, skin and nails. The normal functioning of 
the immune defense requires intact PRRs, including 
Dectin-1, and signal transduction, including CARD9. 
Th17 cells are generated and maintained, which requires 
normal IL-23 signaling (that is, normal IL12B and 
IL12RB1 gene products). Signal transduction requires 
normal STAT1 (no gain-of-function) and normal STAT3 
(no loss-of-function) activity. Finally, IL-17 and IL-17R 
are functional without the presence of blocking 
antibodies (Figure 1).
Use of biologic therapy to treat autoimmune diseases 
and diseases of abnormal inflammation has been on the 
rise. Some adverse effects of these medications are 
known based on vigorous clinical trials, but others can be 
extrapolated from an expanded understanding of the 
complex mechanisms of the immune system. In the case 
of therapy targeting the IL-17 pathway, increased 
susceptibility to CMC should be anticipated. Prompt 
recog nition and treatment of symptoms of mucocuta-
neous candidiasis are likely to increase the tolerability and 
safety of these medications. Some patients with recurrent 
issues may further benefit from antifungal prophylaxis. 
Prophylaxis could likely be targeted at mucosal surfaces, 
since disseminated or invasive candidiasis is rarely seen 
in patients with isolated defects in IL-17 signaling or CD4 
deficiency. However, increased risk of candidiasis, poten-
tially even disseminated disease, may occur in patients on 
combination immunosuppressive therapy. For example, 
IL-17 blockade could increase the rate of asymptomatic 
colonization without signs of overt disease. With the 
addition of therapeutic agents targeting other segments 
of the immune system, asymptomatic colonization 
predisposes patients to invasive disease. Consequently, 
careful consideration of the cumulative risk for fungal 
infections is warranted.
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